Abstract
The immunological bone marrow (BM) microenvironment plays a major role in controlling growth and survival of clonal plasma cells (PC); this might translate into different patterns of expression of molecules involved in immune responses on PC from different types of monoclonal gammopathies (MG). We have studied the expression of a group of nine such molecules on both BMPC and the plasma of 61 newly diagnosed MG patients (30 MG of undetermined significance (MGUS), 27 multiple myeloma (MM) and four plasma cell leukemia (PCL)) and five normal individuals. Clonal PC from all MG displayed significantly increased levels of CD56, CD86 and CD126, and decreased amounts of CD38 (P<0.001). Additionally, HLA-I and β2-microglobulin were abnormally highly expressed in MGUS, while CD40 expression was decreased in MM and PCL (P<0.05). Interestingly, a progressive increase in the soluble levels of β2-microglobulin was found from MGUS to MM and PCL patients (P=0.03). In contrast, all groups showed similar surface and soluble amounts of CD126, CD130 and CD95, except for increased soluble levels of CD95 observed in PCL. Overall, those phenotypic differences are consistent with increased antigen presentation and costimulatory capacities in MGUS, which progressively deteriorate in malignant MG (MM and PCL).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kyle RA . The monoclonal gammopathies. Clin Chem 1994; 40: 2154–2161.
The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma group. Br J Haematol 2003; 121: 749–757.
Kyle RA . Monoclonal gammopathies of undetermined significance. Baillerés Clin Haematol 1995; 8: 761–781.
Ocqueteau M, Orfao A, Almeida J, Bladé J, Gonzalez M, García-Sanz R et al. Immunophenotypic characteristics of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655–1664.
Sezer O, Heider U, Zarski I, Possinger K . Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica 2001; 86: 837–843.
Costello R, Sainty D, Bouabdallah R, Fermard JP, Delmer A, Diviné M et al. Primary plasma cell leukaemia: a report of 18 cases. Leukemia Res 2001; 25: 103–107.
Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032–1037.
Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC . Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607–618.
Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathies of undetermined significance. Blood 2002; 100: 1417–1424.
Kuehl WM, Bergsagel PL . Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–187.
Grigorieva I, Thomas X, Epstein J . The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998; 6: 597–603.
Nefedova Y, Landowski TH, Dalton WS . Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanism. Leukemia 2003; 17: 1175–1182.
Ghia P, Granziero L, Chilosi M, Caligaris-Cappio F . Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 2002; 12: 149–155.
San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455.
Hallek M, Bergsagel PL, Anderson K . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.
Yi Q, Dabadghao S, Östeborg A, Bergenbrant S, Holm G . Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 1997; 90: 1960–1967.
Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 1999; 163: 514–524.
Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR et al. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994; 152: 117–128.
Brown RD, Pope B, Yuen E, Gibson J, Joshua DE . The expression of T cell related costimulatory molecules in multiple myeloma. Leukemia Lymphoma 1998; 31: 379–384.
Pellat-Deceunyck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597–2603.
Berenson JR, Sjak-Shie NN, Vescio RA . The role of human and viral cytokines in the pathogenesis of multiple myeloma. Semin Cancer Biol 2000; 10: 383–391.
Pope B, Brown D, Gibson J, Yuen E, Joshua DE . B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumour immunotherapy. Blood 2000; 96: 1274–1279.
Perosa F, Luccarelli G, Prete M, Ferrone S, Dammacco F . Increased serum levels of β2-microglobulin-free HLA class I heavy chain in multiple myeloma. Br J Haematol 1999; 106: 987–994.
Bataille R, Grenier J, Sany J . Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment – a prospective study of 160 patients. Blood 1984; 63: 468–476.
Rawstron AC, Fenton JAL, Ashcroft JA, English A, Jones RA, Richards SJ et al. The interleukin receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96: 3880–3886.
Barillé S, Thabard W, Robillard N, Moreau P, Pineau D, Harousseau JL et al. CD130 rather than CD126 expression is associated with disease activity in multiple myeloma. Br J Haematol 1999; 106: 532–535.
Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A . The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998; 82: 1860–1866.
Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A et al. Expression of Fas7Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995; 86: 1939–1945.
Nocito M, Montalbán C, González-Porque P, Villar ML . Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 1997; 58: 106–111.
Hooper NM, Karran EH, Turner AJ . Membrane protein secretases. Biochem J 1997; 321: 265–279.
Dhodapkar MV, Krasovsky J, Osman K, Geller MD . Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 11: 1753–1757.
Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F et al. Soluble HLA clas I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL–Fas interaction. Blood 2002; 100: 4098–4107.
Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95+) T lymphocytes. Int Immunol 2000; 12: 195–203.
Xie J, Wang Y, Freeman III ME, Bartologie B, Yi Q . β2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003; 101: 4005–4012.
Bubenik J . MHC class I down-regulation: tumor escape from immune surveillance? Int J Oncol 2004; 25: 487–491.
Dunn GP, Old LJ, Schreiber RD . The three es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329–360.
Bashey A, Cantwell MJ, Kipps TJ . Adenovirus transduction to effect CD40 improves the immune stimulatory activity of myeloma cells. Br J Haematol 2002; 118: 506–513.
Bergamo A, Bataille R, Pellat-Deceunyck C . CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 1997; 97: 652–655.
Sojka DK, Donepudi M, Buestone JA, Mokyr MB . Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 2000; 164: 6230–6236.
Funaro A, Malavasi F . Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker. J Biol Regul Homeost Agents 1999; 13: 54–61.
Vallario A, Chilosi M, Adami F, Motagana L, Deaglio S, Malavasi F et al. Human myeloma cells express the CD38 ligand CD31. Br J Haematol 1999; 105: 441–444.
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–1762.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Pérez-Andrés, M., Almeida, J., Martín-Ayuso, M. et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19, 449–455 (2005). https://doi.org/10.1038/sj.leu.2403647
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403647
Keywords
This article is cited by
-
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Journal of Hematology & Oncology (2022)
-
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Blood Cancer Journal (2018)
-
RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms
InFo Onkologie (2017)
-
Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders
Indian Journal of Hematology and Blood Transfusion (2017)
-
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Cellular and Molecular Life Sciences (2016)